Bright Minds Biosciences (TSE:DRUG)
:DRUG
Top Page
Bright Minds Biosciences
(DRUG)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$95.00
▼(-17.86% Downside)
Action:ReiteratedDate:02/18/26
The score is primarily constrained by pre-revenue operations with sharply higher recent losses and ongoing cash burn, which dominate near-term financial performance. A very strong, low-debt balance sheet partially offsets these risks by improving funding flexibility. Technical indicators are mildly bearish and valuation metrics are weak due to negative earnings and no stated dividend yield.
Positive Factors
Very low leverage / strong balance sheet
Extremely low debt and a large equity base give Bright Minds durable financial flexibility. Low leverage reduces refinancing and interest‑rate risk, allowing the firm to prioritize R&D and clinical programs without material near‑term debt service constraints over the next several quarters.
Negative Factors
Pre‑revenue with widening losses
The company remains pre‑revenue while operating losses have expanded sharply, increasing reliance on external capital. Sustained negative net income at this scale raises dilution risk, compresses runway absent financings, and places pressure on execution milestones to justify further investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / strong balance sheet
Extremely low debt and a large equity base give Bright Minds durable financial flexibility. Low leverage reduces refinancing and interest‑rate risk, allowing the firm to prioritize R&D and clinical programs without material near‑term debt service constraints over the next several quarters.
Read all positive factors
Bright Minds Biosciences (DRUG) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.13B
Dividend YieldN/A
Average Volume (3M)451.00
Price to Earnings (P/E)―
Beta (1Y)22.52
Revenue GrowthN/A
EPS Growth-43.64%
CountryCA
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.97
Shares Outstanding9,787,161
10 Day Avg. Volume620
30 Day Avg. Volume451
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.07
Price to Sales (P/S)0.00
P/FCF Ratio-66.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$192.89Price Target Upside66.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.53
Revenue Forecast (FY)N/A
Bright Minds Biosciences Business Overview & Revenue Model
Company Description
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-H...
How the Company Makes Money
null...
Bright Minds Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
78
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Dec 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -55.34K | -76.87K | -73.36K | -72.45K | -6.04K | 0.00 |
| EBITDA | -19.14M | -13.86M | -2.72M | -7.28M | -14.73M | 0.00 |
| Net Income | -19.84M | -12.23M | -2.80M | -7.37M | -15.19M | -8.52M |
Balance Sheet | ||||||
| Total Assets | 90.88M | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M |
| Cash, Cash Equivalents and Short-Term Investments | 89.05M | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Total Debt | 104.90K | 125.78K | 118.96K | 73.55K | 139.91K | 0.00 |
| Total Liabilities | 1.60M | 2.38M | 568.26K | 280.86K | 1.54M | 638.57K |
| Stockholders Equity | 89.28M | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M |
Cash Flow | ||||||
| Free Cash Flow | -13.01M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Operating Cash Flow | -13.01M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 46.92M | 85.57M | 810.57K | 2.19M | 5.20M | 26.06M |
Bright Minds Biosciences Technical Analysis
Positive
115.66
Price Trends
106.74
Positive
108.34
Positive
84.20
Positive
Market Momentum
1.48
Negative
60.72
Neutral
94.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DRUG, the sentiment is Positive. The current price of 115.66 is above the 20-day moving average (MA) of 102.80, above the 50-day MA of 106.74, and above the 200-day MA of 84.20, indicating a bullish trend. The MACD of 1.48 indicates Negative momentum. The RSI at 60.72 is Neutral, neither overbought nor oversold. The STOCH value of 94.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DRUG.
Bright Minds Biosciences Risk Analysis
Bright Minds Biosciences disclosed 26 risk factors in its most recent earnings report. Bright Minds Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bright Minds Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
TSE:DRUG
Bright Minds Biosciences
115.66
71.24
160.38%
TSE:ENBI
Entheon Biomedical
0.10
-0.03
-23.08%
TSE:MYND
MYND Life Sciences
0.07
0.04
133.33%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.02
-66.67%
TSE:MBIO
Mindbio Therapeutics Corp.
1.10
-2.90
-72.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.